Drug class
Selective estrogen receptor degrader (SERD); oral endocrine antineoplastic
Mechanism of action
Binds to the oestrogen receptor and promotes receptor degradation, reducing oestrogen-receptor signalling in hormone-receptor-positive breast cancer cells.
General use cases
- In combination with abemaciclib, palbociclib or ribociclib for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer after detection of an ESR1 mutation during first-line aromatase-inhibitor plus CDK4/6-inhibitor therapy, without disease progression; the authorisation is under accelerated/conditional approval frameworks and requires current product-label confirmation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
